Immunomedics, Inc. Reports That UCB Group Announces New Results From Phase 2B Open-Label Extension Study Evaluating the Long-Term Effects of Epratuzumab in SLE

Published: Jun 13, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MORRIS PLAINS, N.J., June 13, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU),a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that UCB (Brussels:UCB), announced new data from an open-label extension (SL0008) of the EMBLEMâ„¢ phase 2b study evaluating the long-term effects of epratuzumab treatment in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). The primary outcome of outcome of the open-label extension was to assess the safety of epratuzumab in patients with SLE.4

Help employers find you! Check out all the jobs and post your resume.

Back to news